CAMBRIDGE, Mass., March 19, 2021 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer and Michael Panzara, MD, MPH, Chief Medical Officer and Head of Therapeutics Discovery and Development are scheduled to participate virtually in an analyst-led fireside chat at the Third Annual Stifel CNS Day on Wednesday, April 1, 2021 at 11:30 a.m. ET.
A live webcast of the presentation will be available on the investor relations page of the Wave Life Sciences corporate website at http://ir.wavelifesciences.com. A replay of the presentation will be archived and available at that site for 90 days following the event.
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit www.wavelifesciences.com and follow Wave on Twitter @WaveLifeSci.
Investor Contact:
Kate Rausch
617-949-4827
krausch@wavelifesci.com
Media Contact:
Alicia Suter
617-949-4817
asuter@wavelifesci.com
COLD SPRING HARBOR, N.Y., June 17, 2024 /PRNewswire/ -- Things aren't always as they seem. Take…
AMSTERDAM, June 17, 2024 /PRNewswire/ -- Monday, at HLTH Europe, the Trustworthy & Responsible AI Network…
DUBAI, UAE, June 17, 2024 /PRNewswire/ -- XRP Healthcare proudly announces the release of Issue…
Vancouver, British Columbia--(Newsfile Corp. - June 17, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB:…
At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response…
Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK…